title: Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.
authors: K
authors: K
authors: Aksu
authors: E
authors: E
authors: Kurt
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects; D055963:Asthma, Aspirin-Induced / Q000188:drug therapy*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D016753:Interleukin-10 / Q000096:biosynthesis / Q000097:blood; D008875:Middle Aged; D000069444:Omalizumab
chemical_list: D018926:Anti-Allergic Agents; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; C508609:IL10 protein, human; D016753:Interleukin-10; D000069444:Omalizumab; D007073:Immunoglobulin E; D001241:Aspirin